2nd ESMO Consensus Conference on Lung Cancer: non-small-cell lung cancer first-line/second and further lines of treatment in advanced disease

被引：228

作者：

Besse, B. ^{[1
]}

Adjei, A. ^{[2
]}

Baas, P. ^{[3
]}

Meldgaard, P. ^{[4
]}

Nicolson, M. ^{[5
]}

Paz-Ares, L. ^{[6
]}

Reck, M. ^{[7
]}

Smit, E. F. ^{[8
]}

Syrigos, K. ^{[9
]}

Stahel, R. ^{[10
]}

Felip, E. ^{[11
]}

Peters, S. ^{[12
]}

机构：

[1] Gustave Roussy, Dept Canc Med, Thorac Grp, Villejuif, France

[2] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[3] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands

[4] Aarhus Univ Hosp, DK-8000 Aarhus, Denmark

[5] Aberdeen Royal Infirm, Anchor Unit, Aberdeen, Scotland

[6] Hosp Univ Virgen del Rocio, Seville, Spain

[7] Krankenhaus Grosshansdorf, Dept Thorac Oncol, Grosshansdorf, Germany

[8] Vrije Univ, Med Ctr, Dept Pulm Dis, Amsterdam, Netherlands

[9] Athens Chest Hosp Sotiria, Oncol Unit, Dept Med 3, Athens, Greece

[10] Univ Zurich Hosp, Clin Oncol, CH-8091 Zurich, Switzerland

[11] Vall DHebron Univ Hosp, Barcelona, Spain

[12] CHU Vaudois, Dept Oncol, CH-1011 Lausanne, Switzerland

来源：

ANNALS OF ONCOLOGY | 2014年 / 25卷 / 08期

关键词：

ESMO; consensus; non-small-cell lung cancer; first line; second line; further lines; PHASE-III TRIAL; PLATINUM-BASED CHEMOTHERAPY; CISPLATIN PLUS GEMCITABINE; TYROSINE KINASE INHIBITORS; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; DOUBLE-BLIND; OPEN-LABEL; COMPARING CISPLATIN; ACQUIRED-RESISTANCE;

D O I：

10.1093/annonc/mdu123

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

To complement the existing treatment guidelines for all tumour types, ESMO organises consensus conferences to focus on specific issues in each type of tumour. The 2nd ESMO Consensus Conference on Lung Cancer was held on 11-12 May 2013 in Lugano. A total of 35 experts met to address several questions on non-small-cell lung cancer (NSCLC) in each of four areas: pathology and molecular biomarkers, first-line/second and further lines of treatment in advanced disease, early-stage disease and locally advanced disease. For each question, recommendations were made including reference to the grade of recommendation and level of evidence. This consensus paper focuses on first line/second and further lines of treatment in advanced disease.

引用

页码：1475 / 1484

页数：10

共 68 条

[1]

Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay [J].

Arcila, Maria E. ;

Oxnard, Geoffrey R. ;

Nafa, Khedoudja ;

Riely, Gregory J. ;

Solomon, Stephen B. ;

Zakowski, Maureen F. ;

Kris, Mark G. ;

Pao, William ;

Miller, Vincent A. ;

Ladanyi, Marc .

CLINICAL CANCER RESEARCH, 2011, 17 (05) :1169-1180

[2]

Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis [J].

Ardizzoni, Andrea ;

Boni, Luca ;

Tiseo, Marcello ;

Fossella, Frank V. ;

Schiller, Joan H. ;

Paesmans, Marianne ;

Radosavljevic, Davorin ;

Paccagnella, Adriano ;

Zatloukal, Petr ;

Mazzanti, Paola ;

Bisset, Donald ;

Rosell, Rafael .

JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (11) :847-857

[3]

Pemetrexed Versus Pemetrexed and Carboplatin As Second-Line Chemotherapy in Advanced Non-Small-Cell Lung Cancer: Results of the GOIRC 02-2006 Randomized Phase II Study and Pooled Analysis With the NVALT7 Trial [J].

Ardizzoni, Andrea ;

Tiseo, Marcello ;

Boni, Luca ;

Vincent, Andrew D. ;

Passalacqua, Rodolfo ;

Buti, Sebastiano ;

Amoroso, Domenico ;

Camerini, Andrea ;

Labianca, Roberto ;

Genestreti, Giovenzio ;

Boni, Corrado ;

Ciuffreda, Libero ;

Di Costanzo, Francesco ;

de Marinis, Filippo ;

Crino, Lucio ;

Santo, Antonio ;

Pazzola, Antonio ;

Barbieri, Fausto ;

Zilembo, Nicoletta ;

Colantonio, Ida ;

Tibaldi, Carmelo ;

Mattioli, Rodolfo ;

Cafferata, Mara A. ;

Camisa, Roberta ;

Smit, Egbert F. .

JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (36) :4501-4507

[4]

Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: A systematic review and meta-analysis of individual patient data from 16 randomized controlled trials - NSCLC meta-analyses collaborative group [J].

Burdett, S. ;

Stephens, R. ;

Stewart, L. ;

Tierney, J. ;

Auperin, A. ;

Le Chevalier, T. ;

Le Pechoux, C. ;

Pignon, J. P. ;

Arriagada, R. ;

Higgins, J. ;

Johnson, D. ;

van Meerbeeck, J. ;

Parmar, M. ;

Souhami, R. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (28) :4617-4625

[5]

Impact of Systematic EGFR and KRAS Mutation Evaluation on Progression-Free Survival and Overall Survival in Patients with Advanced Non-Small-Cell Lung Cancer Treated by Erlotinib in a French Prospective Cohort (ERMETIC Project-Part 2) [J].

Cadranel, Jacques ;

Mauguen, Audrey ;

Faller, Michele ;

Zalcman, Gerard ;

Buisine, Marie-Pierre ;

Westeel, Virginie ;

Longchampt, Elisabeth ;

Wislez, Marie ;

Coudert, Bruno ;

Daniel, Catherine ;

Chetaille, Bruno ;

Michiels, Stephane ;

Blons, Helene ;

Solassol, Jerome ;

De Fraipont, Florence ;

Foucher, Pascal ;

Urban, Thierry ;

Lacroix, Ludovic ;

Poulot, Virginie ;

Quoix, Elisabeth ;

Antoine, Martine ;

Danton, Guillaume ;

Morin, Franck ;

Chouaid, Christos ;

Pignon, Jean-Pierre .

JOURNAL OF THORACIC ONCOLOGY, 2012, 7 (10) :1490-1502

[6]

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study [J].

Cappuzzo, Federico ;

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Szczesna, Aleksandra ;

Juhasz, Erzsebet ;

Esteban, Emilio ;

Molinier, Olivier ;

Brugger, Wolfram ;

Melezinek, Ivan ;

Klingelschmitt, Gaelle ;

Klughammer, Barbara ;

Giaccone, Giuseppe .

LANCET ONCOLOGY, 2010, 11 (06) :521-529

[7]

Disease Flare after Tyrosine Kinase Inhibitor Discontinuation in Patients with EGFR-Mutant Lung Cancer and Acquired Resistance to Erlotinib or Gefitinib: Implications for Clinical Trial Design [J].

Chaft, Jamie E. ;

Oxnard, Geoffrey R. ;

Sima, Camelia S. ;

Kris, Mark G. ;

Miller, Vincent A. ;

Riely, Gregory J. .

CLINICAL CANCER RESEARCH, 2011, 17 (19) :6298-6303

[8]

Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study [J].

Ciuleanu, Tudor ;

Stelmakh, Lilia ;

Cicenas, Saulius ;

Miliauskas, Skaidrius ;

Grigorescu, Alexandru Calin ;

Hillenbach, Carina ;

Johannsdottir, Hrefna Kristin ;

Klughammer, Barbara ;

Esteban Gonzalez, Emilio .

LANCET ONCOLOGY, 2012, 13 (03) :300-308

[9]

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study [J].

Ciuleanu, Tudor ;

Brodowicz, Thomas ;

Zielinski, Christoph ;

Kim, Joo Hang ;

Krzakowski, Maciej ;

Laack, Eckart ;

Wu, Yi-Long ;

Bover, Isabel ;

Begbie, Stephen ;

Tzekova, Valentina ;

Cucevic, Branka ;

Pereira, Jose Rodrigues ;

Yang, Sung Hyun ;

Madhavan, Jayaprakash ;

Sugarman, Katherine P. ;

Peterson, Patrick ;

John, William J. ;

Krejcy, Kurt ;

Belani, Chandra P. .

LANCET, 2009, 374 (9699) :1432-1440

[10]

Optimal duration of first-line chemotherapy for advanced non-small cell lung cancer: A systematic review with meta-analysis [J].

da Silveira Nogueira Lima, Joao Paulo ;

dos Santos, Lucas Vieira ;

Sasse, Emma Chen ;

Sasse, Andre Deeke .

EUROPEAN JOURNAL OF CANCER, 2009, 45 (04) :601-607

← 1 2 3 4 5 6 7 →